Pan Yu, Liu Zhao, Wang Yijie, Zhang Linshen, Chua Niying, Dai Lei, Chen Jun, Ho Chun Loong
Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China.
School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Front Bioeng Biotechnol. 2021 Nov 30;9:779018. doi: 10.3389/fbioe.2021.779018. eCollection 2021.
Chronic inflammation is considered a pressing health issue that needs resolving. Inflammatory disease such as inflammatory bowel disease requires a long-term medical regimen to prevent disease progression. Conventionally, lactoferrin is used to treat mild gastrointestinal tract and skin inflammation. Protease-digested lactoferrin fragments often exhibit improved therapeutic properties compared to full-length lactoferrin (flHLF). However, there are no studies on the use of protease-digested lactoferrin fragments to treat inflammation. Herein, we assess the anti-inflammatory properties of engineered recombinant lactoferrin fragments (rtHLF4, rteHLF1, and rpHLF2) on non-malignant colonic fibroblast cells and colorectal cancer cells. We found that rtHLF4 is 10 times more effective to prevent inflammation compared to flHLF. These results were investigated by looking into the reactive oxygen species (ROS) production, angiogenesis activity, and cellular proliferation of the treated cells. We have demonstrated in this study the anti-inflammatory properties of the flHLF and the various lactoferrin fragments. These results complement the anti-cancer properties of these proteins that were demonstrated in an earlier study.
慢性炎症被认为是一个亟待解决的健康问题。诸如炎症性肠病之类的炎性疾病需要长期的药物治疗方案来防止疾病进展。传统上，乳铁蛋白用于治疗轻度胃肠道和皮肤炎症。与全长乳铁蛋白（flHLF）相比，蛋白酶消化的乳铁蛋白片段通常表现出更好的治疗特性。然而，尚无关于使用蛋白酶消化的乳铁蛋白片段治疗炎症的研究。在此，我们评估了工程重组乳铁蛋白片段（rtHLF4、rteHLF1和rpHLF2）对非恶性结肠成纤维细胞和结肠癌细胞的抗炎特性。我们发现，与flHLF相比，rtHLF4预防炎症的效果要高10倍。通过研究处理后细胞的活性氧（ROS）产生、血管生成活性和细胞增殖来探究这些结果。我们在本研究中证明了flHLF和各种乳铁蛋白片段的抗炎特性。这些结果补充了这些蛋白质在早期研究中所证明的抗癌特性。
